Evolution of immuno-oncology
Marc Voigt and Frédéric Triebel, MD Ph.D.
Immuno-oncology did not exist four years ago, it’s a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology RD. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).